Vasant Narasimhan

Chief Executive Officer, Novartis

Vas was appointed CEO in February 2018 after previously serving as Global Head of Drug Development and Chief Medical Officer at Novartis. In 2018, four additional Novartis products reached blockbuster status, and the company further invested in advanced therapy, including acquiring AveXis gene therapy, AAA and Endocyte radioligand therapies, and expanding global manufacturing capacity for Kymriah.

Part of the Power List 2019

Breakthroughs at the bench, novel technologies and groundbreaking policies and regulation have helped the pharma industry grow from strength to strength. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.

Go to The Power List 2019